Gaming and Abuse of Orphan Drugs

Pattern of gaming the system by slicing and dicing indications so that drugs qualify for lucrative orphan status benefits and getting taxpayer subsidies for blockbuster drugs, says a veteran scientist in USA. Companies are intentionally exploiting the law by putting up an initial listing of only single narrow indication for an orphan drugs use, which is just enough to qualify for "orphan" drug designation. Under the terms of this act, companies can receive federal taxpayer subsidies of up to half a million dollars a year for up to four years per drug, large tax credits and waivers of marketing application fees that can cost more than $2 million. In addition, the Food and Drug Administration (FDA) can grant companies seven years of marketing exclusivity for an orphan drug to ensure they recoup the costs of research and development. When those financial incentives become sort of an investment opportunity to take advantage of the Orphan Drug Act. The review found that orphan drug spending in the United States totalled $15 billion in 2007 and $30 billion in 2013, an increase from 4.8 percent of total pharmaceutical spending to 8.9 percent. The current study projects orphan drug spending will remain fairly stable as a proportion of total drug spending. That stands in contrast to other published reports that estimate orphan drugs will account for 20 percent of worldwide spending on drugs (other than generics) by 2020.

  • Financial incentives
  • Recouping the costs of research and development for orphan drugs
  • Forecasts of amount to be spent on orphan drugs by 2020

Related Conference of Gaming and Abuse of Orphan Drugs

October 24-25, 2018

13th International Conference on Biopharma and Biotherapeutics

Boston, Massachusetts, USA
November 05-07, 2018

18th Annual Pharma Middle East Congress

Radisson Blu Hotel, Yas Island, Abu Dhabi, UAE
November 14-15, 2018

13th World Congress on Pharmacology and Toxicology

Melbourne, Australia
November 15-16, 2018

9th Global Experts Meeting on Neuropharmacology

Berlin, Germany
January 30-31, 2019

19th World Congress on Advances in Pharmaceutical Sciences

Seoul, South Korea
January 31-February 01, 2019

9th World Congress on Chromatography

Paris | France
February 20-21, 2019

World Congress on Drug Discovery and Drug Design

Singapore
February 22-23, 2019

13th World Drug Delivery Summit

San Francisco, USA
Feb 28-March 01, 2019

International Conference on Bio-Pharmaceuticals

Osaka, Japan
March 25-26, 2019

World Congress on Pharmaceutical Biotechnology & Bioengineering

Orlando, Florida, USA
March 27-28, 2019

5th International Conference on Clinical Pharmacy and
Health Care

San Antonio, Texas, USA
April 04-06, 2019

4th Annual Congress on Nanomedicine and Drug Delivery

Auckland, NewZealand
April 15-16, 2019

12th European Biosimilars Congress

Berlin, Germany
April 17-18, 2019

11th World Congress on Pharmacology & Therapeutics

Montreal, Canada
April 17-18, 2019

Annual Neurochemistry and Neuropharmacology Congress

| Montreal, Canada
April 17-18, 2019

International Conference on Global Analytica

Osaka, Japan

April 22-23, 2019

6th World Congress on Drug Discovery & Toxicology

Abu Dhabi, UAE
May 9-11, 2019

11th World Congress on Neuropharmacology

Prague, Czech Republic
May 20-22, 2019

21st Annual European Pharma Congress

Zurich, Switzerland
April 22-24, 2019

20th Asia-Pacific Pharma Congress

Tokyo, Japan
March 22-23, 2019

5th International Conference on Antibiotics

Orlando, USA
June 17-18, 2019

7 th European Biopharma Congress

Stockholm, Sweden
June 17-18, 2019

14th World Congress on Pharmacology and Drug Safety

Lisbon, Portugal
June 27-29, 2019

18th Annual Congress on Pharmaceutics & Drug Delivery Systems

Amsterdam, Netherlands
July 19-20, 2019

8th International Conference on Clinical Trials

| Atlanta, USA

August 19-20, 2019

24th World Congress on Pharmacology

Vienna, Austria

Gaming and Abuse of Orphan Drugs Conference Speakers

Recommended Sessions

Related Journals

Are you interested in